Takeda, a global biopharmaceutical company with a manufacturing site in Stanton Springs, unveiled its new Biomedical Waste ...
Russell Henley faced one shot he hardly ever practices. On another, he figured he had little chance for the ball to stay on ...
Virginia Cancer Specialists, a respected leader in providing community-based cancer care in Northern VA for more than ...
GRIN Therapeutics, Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, today announced that the U.S. Food and ...
Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...
The Aluminum Foil Packaging Market is valued at approximately $26.1 billion in 2024, with expectations to reach around $39.2 billion by 2034. This growth represents a Compound Annual Growth Rate (CAGR ...
15d
Golf Monthly on MSNAngel Yin Hangs On For Second LPGA Tour Title Despite Sponsor Invite's Closing 61The American narrowly claimed the Honda LPGA Thailand prize ahead of Japan's Akie Iwai - who almost snatched victory away via ...
16don MSN
Scores from the LPGA Tour Honda LPGA Thailand on Saturday -21 Angel Yin (USA) 67 64 64 -16 Akie Iwai (Japan) 62 67 71 -15 Moriya Jutanugarn (Thailand) 66 66 69 Atthaya Thitikul (Thailand) 68 64 69 -13 ...
LPGA Tour rookie Rio Takeda carded a 69 to take a two-stroke lead after three rounds on Saturday at the Blue Bay LPGA on Hainan Island, China.
Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...
Takeda’s (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit and chair of the Plasma Protein ...
On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results